Read by QxMD icon Read

European Journal of Clinical Pharmacology

Jila Agah, Roya Baghani, Mohammad Hassan Rakhshani, Abolfazl Rad
The original publication of this paper contains an error.
November 16, 2017: European Journal of Clinical Pharmacology
Andrea V Margulis, Jesper Hallas, Anton Pottegård, Nina Sahlertz Kristiansen, Willem Jan Atsma, Billy Franks, Milbhor D'Silva, Cristina Varas-Lorenzo, Susana Perez-Gutthann, Alejandro Arana
PURPOSE: The purpose of this study is to explore the cardiovascular safety of antimuscarinic drugs to treat overactive bladder (OAB) in Denmark. METHODS: This was a cohort study using data recorded in Danish registries from patients newly exposed to darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium in 2004-2012. We estimated crude and standardized incidence rates (IRs) for acute myocardial infarction (AMI); stroke; cardiovascular mortality; major adverse cardiac events (MACE, a combined endpoint of the previous three outcomes); and all-cause death for the individual and combined drugs...
November 13, 2017: European Journal of Clinical Pharmacology
Irene Eriksson, Thomas Cars, Fredrik Piehl, Rickard E Malmström, Björn Wettermark, Mia von Euler
PURPOSE: To describe patients initiating dimethyl fumarate (DMF) and measure persistence with DMF, discontinuation, and switching in treatment-naïve DMF patients and patients switching to DMF from other multiple sclerosis disease-modifying treatments (DMTs). METHODS: A population-based cohort study of all Stockholm County residents initiating DMF from 9 May 2014 until 31 May 2017. All data were derived from a regional database that collects individual-level data on healthcare and drug utilization of all residents...
November 11, 2017: European Journal of Clinical Pharmacology
Farid Kheloufi, Anne Default, Bruno Perrouty, Olivier Blin, Joëlle Micallef
No abstract text is available yet for this article.
November 11, 2017: European Journal of Clinical Pharmacology
C Mestres Gonzalvo, V Milosevic, B P C van Oijen, H A J M de Wit, K P G M Hurkens, W J Mulder, R Janknegt, J M G A Schols, F R Verhey, B Winkens, P H M van der Kuy
PURPOSE: The chronic use of benzodiazepines and benzodiazepine-related drugs (BZ/Z) in older people is common and not without risks. The objective of this study was to evaluate whether the implementation of a clinical rule promotes the discontinuation of chronically used BZ/Z for insomnia. METHODS: A clinical rule, generating an alert in case of chronic BZ/Z use, was created and applied to the nursing home (NH) setting. The clinical rule was a one-off intervention, and alerts did not occur over time...
November 10, 2017: European Journal of Clinical Pharmacology
Fredrik N Albach, Frank Wagner, Andreas Hüser, Julia Igel, David Joseph, James Hilbert, Corinna Schoelch, Steven J Padula, Jürgen Steffgen
PURPOSE: The CD40-CD40L pathway is a promising treatment target for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis. The safety, pharmacokinetics and pharmacodynamics of BI 655064, a novel humanised antagonistic anti-CD40 monoclonal antibody, were investigated in this first-in-human trial. METHODS: Healthy male subjects (n = 72) were randomised 3:1, within each BI 655064 dose group, to single intravenous (IV; 0...
November 10, 2017: European Journal of Clinical Pharmacology
Rafael Dal-Ré
No abstract text is available yet for this article.
November 9, 2017: European Journal of Clinical Pharmacology
Florence Moulis, Geneviève Durrieu, Kamel Masmoudi, Marie Gervoise Boyer, Fanny Rocher, François Montastruc, Jean-Louis Montastruc
No abstract text is available yet for this article.
November 6, 2017: European Journal of Clinical Pharmacology
Khedidja Hedna, Karolina Andersson Sundell, Armina Hamidi, Ingmar Skoog, Sara Gustavsson, Margda Waern
PURPOSE: To investigate associations between antidepressant use patterns and risk of fatal and non-fatal suicidal behaviours in older adults who initiated antidepressant therapy. METHOD: A national population-based cohort study conducted among Swedish residents aged ≥ 75 years who initiated antidepressant treatment. Patients who filled antidepressant prescriptions between January 1, 2007 and December 31, 2013 (N = 185,225) were followed until December 31, 2014...
November 4, 2017: European Journal of Clinical Pharmacology
Pernilla J Bjerkeli, Shai Mulinari, Sofia Zettermark, Juan Merlo
PURPOSE: The purpose of this study is to investigate the relationship between sociodemographic factors and pharmacy dispensing of medications for erectile dysfunction (ED) in the general population of middle-aged and elderly men. By considering a number of medical conditions that could promote or contraindicate use of ED medication, the analysis could help capture prescription patterns that might not be explained by medical needs. METHODS: Individual-level pharmacy dispensing data from 2006 for a population-based cohort of 216,148 men aged 45-79 years in the county Scania, Sweden, were analysed...
November 3, 2017: European Journal of Clinical Pharmacology
Xia Yang, Wei Liu, Allie Lyons, Zaiwei Song, Suodi Zhai, Kai Hu
BACKGROUND: The incidence of cytarabine-induced pericarditis is rare. So far, only a few cases have been reported worldwide. DESCRIPTION OF THE CASE: We are reporting a case of a 25-year-old male with acute myeloid leukemia (AML M2a) on chemotherapy who developed acute pericarditis after the administration of a cytarabine-containing regimen. The symptoms gradually improved after symptomatic treatment with steroids and other drugs. CONCLUSIONS: This case demonstrates that, although pericarditis induced by cytarabine is rare, early recognition of this potentially life-threatening complication and appropriate management will usually result in the patient's recovery...
October 27, 2017: European Journal of Clinical Pharmacology
Sarah-Jo Sinnott, Kathleen Bennett, Caitriona Cahir
In the 3rd paragraph and 2nd line of the Conclusion section the correct sentence should be: It is now important to encourage policy and decision makers to facilitate and accommodate future linkage of data.
October 26, 2017: European Journal of Clinical Pharmacology
Thomas M Caparrotta, Daniel J Antoine, James W Dear
PURPOSE: Paracetamol is one of the world's most commonly used drugs. In overdose, it is well established to be hepatotoxic. The aim of this review was to identify factors that have been, or actually are, associated with the development of liver injury after paracetamol exposure in humans. METHOD: Google Scholar and PubMed were searched on various dates between December 2016 and March 2017. Papers identified had their references analysed for further studies that might be relevant...
October 24, 2017: European Journal of Clinical Pharmacology
Katarina Dathe, Christof Schaefer
Since 1988, the German Embryotox institute combines individual counselling of pregnant women and their health care providers (HCP) with research on drug safety in pregnancy. In addition, Embryotox offers web-based information which covers the most important and most frequently requested pharmaceutical substances. In contrast to ready-made drug risk information in package leaflets and other product information, individual counselling considers different clinical settings such as (1) looking for a drug of choice or planning pregnancy under medication, (2) risk assessment of a particular drug that has already been taken during an (unplanned) pregnancy and (3) evaluation of an adverse pregnancy outcome in association with a particular medication...
October 24, 2017: European Journal of Clinical Pharmacology
Jaran Eriksen, Marie-Louise Ovesjö, Martina Vallin, Maria Juhasz-Haverinen, Eva Andersén-Karlsson, Kristina Ateva, Lars L Gustafsson, Malena Jirlow, Pia Bastholm-Rahmner
PURPOSE: Inappropriate use of medicines causes increased morbidity, mortality, adverse drug reactions, therapeutic failures and drug resistance as well as wastes valuable resources. Evidence-based cost-effective treatment recommendations of essential medicines are a way of avoiding these. We assessed primary care prescribers' knowledge about and perceptions of an essential medicines formulary, as well as the reasons for adhering to the recommendations. METHODS: We conducted a web based questionnaire survey targeting all physicians working in the primary healthcare of the Stockholm healthcare region (2...
October 23, 2017: European Journal of Clinical Pharmacology
Wu Yi Zheng, L C Richardson, L Li, R O Day, J I Westbrook, M T Baysari
PURPOSE: Drug-drug interactions (DDIs) are often avoidable and, if undetected, can lead to patient harm. This review aimed to determine the prevalence of potential DDIs (pDDIs), clinically relevant DDIs (DDIs that could lead to measurable patient harm, taking into account the patient's individual clinical profile) and DDIs that resulted in actual patient harm during hospitalisation. METHOD: Four databases were scanned for English papers published from 2000 to 2016...
October 23, 2017: European Journal of Clinical Pharmacology
Feng Xiao, Feng Zhang, Ling-Ling Zhang, Wei Wei
OBJECTIVE: The aim of this study was to investigate the safety, maximum tolerated dose and pharmacokinetics (PK) of iguratimod and the effect of food on PK parameters in healthy adult volunteers. METHODS: This phase 1 study consisted of four parts. Part 1 was a single-ascending dose (3.125, 6.25, 12.5, 25, 50, 75 mg) study to assess the maximum tolerated dose and safety of iguratimod. Part 2 was a single-ascending dose study to analyze the pharmacokinetic (PK) parameters of iguratimod; subjects were divided into three groups, with each group receiving iguratimod at a different dose (25, 50 or 75 mg)...
October 19, 2017: European Journal of Clinical Pharmacology
A Biffi, F Rea, L Scotti, A Mugelli, E Lucenteforte, A Bettiol, A Chinellato, G Onder, C Vitale, N Agabiti, G Trifirò, G Roberto, G Corrao
PURPOSE: The study aimed to fill existing knowledge gaps on the safety of antidepressant drugs (ADs) by estimating the risk of hospitalization for arrhythmia associated with use of selective serotonin reuptake inhibitors (SSRIs) and newer atypical ADs (NAAs) among elderly with previous cardiovascular (CV) events. METHODS: The cohort was composed by 199,569 individuals aged ≥ 65 years from five Italian healthcare territorial units who were discharged for cardiovascular outcomes in the years 2008-2010...
October 18, 2017: European Journal of Clinical Pharmacology
Guillermo Gervasini, Guadalupe García-Pino, Esther Vergara, Sonia Mota-Zamorano, Montserrat García-Cerrada, Enrique Luna
PURPOSE: We aimed to determine whether polymorphisms in CYP3A genes may affect the risk of acute rejection episodes (ARE) in renal transplant recipients treated with calcineurin inhibitors (CNIs). METHODS: One hundred and thirty seven patients and their respective donors were screened, by RT-PCR techniques, for three polymorphisms previously related with CNI pharmacokinetics and pharmacodynamics (CYP3A4*1B, CYP3A4*22 and CYP3A5*3). Genotypes of donors and recipients were associated by logistic regression models with ARE risk and exposure to CNIs...
October 18, 2017: European Journal of Clinical Pharmacology
Victoria C Ziesenitz, Walter E Haefeli, Johannes N van den Anker, Matthias Gorenflo
No abstract text is available yet for this article.
October 13, 2017: European Journal of Clinical Pharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"